Ebribafusp Biosimilar Fusion Protein (C3d) for Research

Cat No.: GMP-Bios-INN-1168

Anti-C3d therapeutic antibody (Pre-made Ebribafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ebribafusp (development codes ADX-097/3d8b) is a chimeric antibody fusion protein targeting complement C3d. It is developed by Q32 Bio for IgA nephropathy, lupus nephritis and other immune-mediated disorders. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1168-1mg 1mg 3090
GMP-Bios-INN-1168-10mg 10mg
GMP-Bios-INN-1168-100mg 100mg
GMP-Bios-INN-1168-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Ebribafusp biosimilar, Fusion Protein targeting C3d: Recombinant therapeutic protein targeting C3/C3b/C3c/CO3
INN Name Ebribafusp
Target C3d
Format Fusion Protein
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure 7ue9:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies Q32 Bio
Conditions Approved na
Conditions Active IgA nephropathy;Lupus nephritis;Membranoproliferative glomerulonephritis;Skin disorders
Conditions Discontinued na
Production na
Development Tech na